

Functional Composite Spacer (Antibiotic Cement Around a Hemiarthroplasty) for the Treatment of Shoulder Infections: Minimum 5-Year Outcomes

Daniel F Schodlbauer, Casey Michelle Beleckas¹, Austin Vegas, Gagan Grewal, Albert Mousad, Jonathan Chad Levy²

¹Levy Shoulder To Hand Center At the Paley Orthoped, ²Levy Shoulder to Hand Center at the Paley Orthopedic & Spine Institute

INTRODUCTION:

Prosthetic joint infection (PJI) remains a challenging complication following shoulder arthroplasty and an ideal treatment protocol has yet to be established. Two-stage revision is a common approach. Historically, the first stage entails placement of an all-cement antibiotic spacer. While prior studies have reported on cement spacers as definitive management, persistent pain and/or inadequate function often result in a request for a second stage procedure. The functional composite spacer consists of a humeral hemiarthroplasty implant with antibiotic cement coated around the stem alone to preserve the metallic humeral head-glenoid articulation. Functional composite spacers have demonstrated improvements in function and motion with high patient satisfaction at 25 months, but longer-term follow-up is needed to better understand the role it may play in the definitive management of shoulder infections. The purpose of this study is to evaluate outcomes at a minimum of 5 years in patients who initially planned to undergo two-stage revision but elected to retain the functional spacer.

METHODS:

A retrospective review of a single institution's shoulder surgery repository from 2007 to 2018 identified 30 patients who underwent placement of a functional composite spacer. Overall, 5 patients underwent second stage reimplantation and 12 patients did not have 5-year follow-up (6 lost to follow-up and 6 deceased). A total 13 patients were included who maintained a functional composite spacer and had minimum 5-year follow-up. Patient-reported outcome measures (American Shoulder and Elbow Surgeons [ASES], Simple Shoulder Test [SST], Single Assessment Numeric Evaluation [SANE], Visual Analog Score [VAS] Function and VAS Pain scores), satisfaction, range of motion, and radiographic estimation of glenoid wear were evaluated.

RESULTS:

Two of 13 patients (15%) required additional surgery: one secondary closure for early superficial wound dehiscence and one revision spacer for pain which cultured negative at revision. There were no re-infections. At most recent follow-up (average of 7.9 ± 1.9 years post-operatively), patient satisfaction was high and significant improvements were noted for ASES (45.4; $p < 0.001$), SST (5.3; $p = 0.003$), SANE (47.3; $p = 0.002$), VAS F (4.9; $p = 0.004$), and VAS P (-4.4; $p = 0.007$) as well as range of motion including abduction (39.2° ; $p = 0.005$) and elevation (65.9° ; $p = 0.005$), as noted in Table 1. At an average radiographic follow-up of 5.7 ± 3.4 years, there was no significant change in humeral head medialization ($p = 0.11$).

DISCUSSION AND CONCLUSION:

The results of this study demonstrate that patients who do not undergo an early revision and retain a functional composite spacer maintain good function and range of motion with minimal pain at mid-term follow-up. These satisfactory outcomes suggest the composite spacer may sufficiently serve as definitive management when appropriate, avoiding the associated cost and risk with additional second-stage surgery.




Figure 1. A flowchart illustrating the selection process for the study. Patients who underwent revision shoulder arthroplasty (2007-2018) were identified. From this group, patients who underwent second stage revision (n=5) and patients who did not have 5-year follow-up (n=12) were excluded. The final group consisted of 13 patients who maintained a functional composite spacer and had minimum 5-year follow-up.



Figure 3. (a) Hemiarthroplasty stem used in the functional composite spacer. (b) Coating of stem with antibiotic cement. (c) Functional composite spacer prior to implantation.

Table 1. Patient Demographics					
Patient	Sex	Age at Surgery (yr)	Time from Surgery to Follow-Up (yr)	Previous Surgery	Operative Findings
1	M	74	9.4	THA	P. aeruginosa
2	M	74	9.4	THA	P. aeruginosa
3	M	74	9.4	THA	P. aeruginosa
4	M	74	9.4	THA	P. aeruginosa
5	M	74	9.4	THA	P. aeruginosa
6	M	74	9.4	THA	P. aeruginosa
7	M	74	9.4	THA	P. aeruginosa
8	M	74	9.4	THA	P. aeruginosa
9	M	74	9.4	THA	P. aeruginosa
10	M	74	9.4	THA	P. aeruginosa
11	M	74	9.4	THA	P. aeruginosa
12	M	74	9.4	THA	P. aeruginosa
13	M	74	9.4	THA	P. aeruginosa

THA, Total Hip Arthroplasty; P. aeruginosa, Pseudomonas aeruginosa.

Table 2. Comparison of Patient Reported Outcomes and Range of Motion					
Patient		Preoperative		Postoperative	
		Mean (SD)	Mean (SD)	Mean (SD)	P
ASES		12.2 (2.2)	45.4 (2.2)	45.4 (2.2)	<0.001
SST		2.2 (2.2)	5.3 (2.2)	5.3 (2.2)	0.003
SANE		25.1 (11.0)	47.3 (11.0)	47.3 (11.0)	0.002
VAS F		5.9 (2.2)	4.9 (2.2)	4.9 (2.2)	0.004
VAS Pain		5.9 (2.2)	4.9 (2.2)	4.9 (2.2)	0.007
Range of Motion					
Abduction (°)		46.2 (14.7)	65.9 (14.7)	65.9 (14.7)	0.005
Flexion (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
Internal Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
External Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
Internal Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
External Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005

ASES, American Shoulder and Elbow Surgeons; SST, Simple Shoulder Test; SANE, Single Assessment Numeric Evaluation; VAS, Visual Analog Scale; SD, Standard Deviation. *P < 0.05 was used as a significance level using the following statistical tests: Student's t-test for continuous data, Fisher's exact test for categorical data.

Table 3. Comparison of Patient Reported Outcomes and Range of Motion					
Patient		Preoperative		Postoperative	
		Mean (SD)	Mean (SD)	Mean (SD)	P
ASES		12.2 (2.2)	45.4 (2.2)	45.4 (2.2)	<0.001
SST		2.2 (2.2)	5.3 (2.2)	5.3 (2.2)	0.003
SANE		25.1 (11.0)	47.3 (11.0)	47.3 (11.0)	0.002
VAS F		5.9 (2.2)	4.9 (2.2)	4.9 (2.2)	0.004
VAS Pain		5.9 (2.2)	4.9 (2.2)	4.9 (2.2)	0.007
Range of Motion					
Abduction (°)		46.2 (14.7)	65.9 (14.7)	65.9 (14.7)	0.005
Flexion (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
Internal Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
External Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
Internal Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005
External Rotation (°)		131.6 (20.4)	131.6 (20.4)	131.6 (20.4)	0.005

ASES, American Shoulder and Elbow Surgeons; SST, Simple Shoulder Test; SANE, Single Assessment Numeric Evaluation; VAS, Visual Analog Scale; SD, Standard Deviation. *P < 0.05 was used as a significance level using the following statistical tests: Student's t-test for continuous data, Fisher's exact test for categorical data.